苓芍枣仁配方颗粒联合酒石酸托特罗定治疗女性膀胱过度活动症随机、双盲对照研究
|
摘要
目的评价苓芍枣仁配方颗粒联合酒石酸托特罗定缓释片治疗女性膀胱过度活动症的临床疗效以及对酒石酸托特罗定缓释片不良反应的缓解作用。方法采用随机、双盲、平行对照研究方法,选择60例女性膀胱过度活动症门诊患者随机分为治疗组及对照组,每组30例。两组均口服酒石酸托特罗定缓释片4mg/d,治疗组口服苓芍枣仁配方颗粒4g,每天2次;对照组口服苓芍枣仁颗粒安慰剂4g,每天2次;连续治疗4周。比较两组治疗前后排尿症状评分、中医证候评分、不良反应评分。结果与本组治疗前比较,两组治疗14、28日排尿症状评分降低(P<0.05);治疗组治疗14、28日中医证候评分降低(P<0.05),治疗14日不良反应评分升高(P<0.05);对照组治疗14、28日不良反应评分明显升高(P<0.05)。与对照组同期比较,治疗组治疗28日排尿症状评分降低(P<0.05),治疗14、28日中医证候评分及不良反应评分降低(P<0.05)。结论苓芍枣仁配方颗粒可改善女性膀胱过度活动症患者排尿症状、中医证候,减轻酒石酸托特罗定不良反应。
Objective To evaluate the therapeutic efficacy of combined therapy with Lingshao Zaoren Formula Granule(LZFG)and Tolterodine Tartrate on female overactive bladder(OAB).Methods Using randomized double-blinded controlled design,60 female patients with OAB were randomly assigned to the treated group and the control group,30 cases in each group.All patients were treated with Tolterodine Tartrate sustained release Tablets(4 mg/d),but to the treated group LZFG(4 g)was given additionally twice every day,while to the control group placebo capsule of equal dosage was given instead.The therapeutic course for all was 4 weeks.The urination symptom score,TCM syndrome score and adverse reaction score were measured before and after treatment.Results Compared with before treatment in the same group,the urination symptom score decreased in both groups after 14 and 28 days of treatment(P<0.05),TCM syndrome score decreased in the treatment group after 14 and 28 days of treatment(P<0.05),and adverse reaction score increased after 14 days of treatment(P<0.05);adverse reaction score in the control group increased after 14 and28 days of treatment(P<0.05).Compared with the control group,the urination symptom score decreased in the treatment group after 28 days of treatment(P<0.05),TCM syndrome score and adverse reaction score decreased after 14 and 28 days of treatment(P<0.05).Conclusions LZFG could improve urination symptom and TCM Syndrome of female overactive bladder,and alleviate adverse reaction of Tolterodine Tartrate.
Objective To evaluate the therapeutic efficacy of combined therapy with Lingshao Zaoren Formula Granule(LZFG)and Tolterodine Tartrate on female overactive bladder(OAB).Methods Using randomized double-blinded controlled design,60 female patients with OAB were randomly assigned to the treated group and the control group,30 cases in each group.All patients were treated with Tolterodine Tartrate sustained release Tablets(4 mg/d),but to the treated group LZFG(4 g)was given additionally twice every day,while to the control group placebo capsule of equal dosage was given instead.The therapeutic course for all was 4 weeks.The urination symptom score,TCM syndrome score and adverse reaction score were measured before and after treatment.Results Compared with before treatment in the same group,the urination symptom score decreased in both groups after 14 and 28 days of treatment(P<0.05),TCM syndrome score decreased in the treatment group after 14 and 28 days of treatment(P<0.05),and adverse reaction score increased after 14 days of treatment(P<0.05);adverse reaction score in the control group increased after 14 and28 days of treatment(P<0.05).Compared with the control group,the urination symptom score decreased in the treatment group after 28 days of treatment(P<0.05),TCM syndrome score and adverse reaction score decreased after 14 and 28 days of treatment(P<0.05).Conclusions LZFG could improve urination symptom and TCM Syndrome of female overactive bladder,and alleviate adverse reaction of Tolterodine Tartrate.
引文
[1]那彦群,叶章群,孙颖浩,等主编.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2013:330-339.
[2]廖利民,鞠彦合.膀胱过度活动症(OAB)研究进展——来自第43届国际尿控协会(ICS)年会的报道[J].现代泌尿外科杂志,2014,19(1):15-18.
[3]王驭良,许克新,胡浩,等.北京地区成年女性膀胱过度活动症流行病学调查及对患者生活质量的影响[J].中华泌尿外科杂志,2010,31(8):550-554.
[4]高宏亮,夏志军.膀胱过度活动症及间质性膀胱炎膀胱灌注治疗的研究进展[J].临床与病理杂志2017,37(8):172-1724.
[5]王阳赟.米拉贝隆在膀胱过度活动症治疗中的研究现状[J].现代泌尿外科杂志,2014,19(8):559-562.
[6]苏鹏超,赵继懋,宋健,等.索非那新联合坦索罗辛治疗前列腺增生伴膀胱过度活动症的有效性Meta分析[J].现代泌尿外科杂志,2015,20(11):794-797.
[7]邵魁卿,李奇,曾凡雄,等.苓芍枣仁颗粒联合酒石酸托特罗定片治疗女性膀胱过度活动症疗效分析[J].国际中医中药杂志,2014,36(10):883-885.
[8]王小龙,何爽.温针灸法治疗老年女性特发性膀胱过度活动症的疗效观察[J].中国老年医学杂志,2016,36(3):1160-1161.
[9]杨尚淇,来永庆,陈月英,等.膀胱过度活动症症状评分表评估膀胱过度活动症的临床研究[J].中华临床医师杂志(电子版),2012,6(16):4675-4678.
[10]方伟林,吕坚伟,蒋晨,等.翁沥通联合托特罗定治疗女性膀胱过度活动症的疗效性和安全性研究[J].现代泌尿外科杂志,2017,22(8):583-589.
[11]张杰,黄捷,潘永军,等.经皮胫神经电刺激治疗女性膀胱过度活动症的临床疗效[J].检验医学与临床,2017,14(15):2177-2179.
[12]Oefelein MG.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder[J].Drug Saf,2011,34(9):733-754.
[13]Knüpfer S,Hamann M,Naumann CM,et al.Therapyrefractory overactive bladder:alternative treatment approaches[J].Urologe A,2011,50(7):806-809.
[14]贾民,张晓宇.中药敷脐联合盆底肌训练治疗女性膀胱过度活动症疗效观察[J].河北中医,2016,38(10):1495-1497.
[15]张春和,李焱风,秦国政,等.1 252例男性更年期综合征中医证候分布规律研究[J].中华中医药杂志,2012,27(2):338-342.
[2]廖利民,鞠彦合.膀胱过度活动症(OAB)研究进展——来自第43届国际尿控协会(ICS)年会的报道[J].现代泌尿外科杂志,2014,19(1):15-18.
[3]王驭良,许克新,胡浩,等.北京地区成年女性膀胱过度活动症流行病学调查及对患者生活质量的影响[J].中华泌尿外科杂志,2010,31(8):550-554.
[4]高宏亮,夏志军.膀胱过度活动症及间质性膀胱炎膀胱灌注治疗的研究进展[J].临床与病理杂志2017,37(8):172-1724.
[5]王阳赟.米拉贝隆在膀胱过度活动症治疗中的研究现状[J].现代泌尿外科杂志,2014,19(8):559-562.
[6]苏鹏超,赵继懋,宋健,等.索非那新联合坦索罗辛治疗前列腺增生伴膀胱过度活动症的有效性Meta分析[J].现代泌尿外科杂志,2015,20(11):794-797.
[7]邵魁卿,李奇,曾凡雄,等.苓芍枣仁颗粒联合酒石酸托特罗定片治疗女性膀胱过度活动症疗效分析[J].国际中医中药杂志,2014,36(10):883-885.
[8]王小龙,何爽.温针灸法治疗老年女性特发性膀胱过度活动症的疗效观察[J].中国老年医学杂志,2016,36(3):1160-1161.
[9]杨尚淇,来永庆,陈月英,等.膀胱过度活动症症状评分表评估膀胱过度活动症的临床研究[J].中华临床医师杂志(电子版),2012,6(16):4675-4678.
[10]方伟林,吕坚伟,蒋晨,等.翁沥通联合托特罗定治疗女性膀胱过度活动症的疗效性和安全性研究[J].现代泌尿外科杂志,2017,22(8):583-589.
[11]张杰,黄捷,潘永军,等.经皮胫神经电刺激治疗女性膀胱过度活动症的临床疗效[J].检验医学与临床,2017,14(15):2177-2179.
[12]Oefelein MG.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder[J].Drug Saf,2011,34(9):733-754.
[13]Knüpfer S,Hamann M,Naumann CM,et al.Therapyrefractory overactive bladder:alternative treatment approaches[J].Urologe A,2011,50(7):806-809.
[14]贾民,张晓宇.中药敷脐联合盆底肌训练治疗女性膀胱过度活动症疗效观察[J].河北中医,2016,38(10):1495-1497.
[15]张春和,李焱风,秦国政,等.1 252例男性更年期综合征中医证候分布规律研究[J].中华中医药杂志,2012,27(2):338-342.